Literature DB >> 9846009

Hypothesis: myelodysplastic syndromes may have a viral etiology.

A Raza1.   

Abstract

An 'initial transforming event(s)' in a pluripotential bone marrow (BM) stem cell confers a growth advantage upon it leading to clonal expansion accompanied by dysplastic maturation resulting in myelodysplastic syndromes (MDS). The nature of this 'initial' event in MDS is obscure. We propose that MDS can begin as a viral disease. It may be a dormant lentivirus which is made oncogenic by 'promoting events' such as immunosuppression, or a second viral infection. The infected cell may not be a BM stem cell, but a cell belonging to the BM stroma or to the immune system. Dysregulated cytokine production as a consequence of the infection can change the BM microenvironment in such a way that optimal growth support is provided only to a rapidly proliferating stem cell. Karyotypically marked (or unmarked) abnormal stem cells may exist or arise frequently but do not thrive in a 'normal' cytokine milieu. However, with the changed BM landscape, these abnormal clones may enjoy a growth advantage leading to a monoclonal hypercellular BM and variable cytopenias. Circumstantial evidence to support the possibility that the initial transforming event in MDS is a viral insult is presented in this hypothesis paper.

Entities:  

Mesh:

Year:  1998        PMID: 9846009     DOI: 10.1016/s0925-5710(98)00051-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  2 in total

Review 1.  Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?

Authors:  Sebastian Stintzing; Ralf Kemmerling; Tobias Kiesslich; Beate Alinger; Matthias Ocker; Daniel Neureiter
Journal:  J Biomed Biotechnol       Date:  2011-05-15

2.  Myelodysplastic syndrome in a kidney transplant recipient after SARS-CoV-2 infection: can SARS-CoV-2 induce myelodysplastic syndrome?

Authors:  Ivana Juric; Lea Katalinic; Vesna Furic-Cunko; Nikolina Basic-Jukic
Journal:  Int Urol Nephrol       Date:  2021-11-23       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.